Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Alimera announces first marketing authorization for Iluvien in E.U.

April 25, 2012

No Comments

Scripps Research receives grant to develop new eye disease treatments

April 24, 2012

No Comments

Senju Pharmaceutical plans new release of ophthalmic solution

April 20, 2012

No Comments

ThromboGenics resubmits BLA for ocriplasmin

April 17, 2012

No Comments

MacuCLEAR to advance MC-1101 to phase III development

April 12, 2012

No Comments

Omeros begins enrollment in second phase III OMS-302 trial

April 11, 2012

No Comments

Preclinical studies demonstrate small molecule's efficacy to treat anterior uveitis

April 10, 2012

No Comments

DARPin-based VEGF inhibitor completes phase IIa trial

April 10, 2012

No Comments

Novartis seeks approval for Lucentis line extension

April 2, 2012

No Comments

JDRF and iCo Therapeutics join to support iDEAL trial

March 29, 2012

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

Alimera announces first marketing authorization for Iluvien in E.U.

Scripps Research receives grant to develop new eye disease treatments

Senju Pharmaceutical plans new release of ophthalmic solution

ThromboGenics resubmits BLA for ocriplasmin

MacuCLEAR to advance MC-1101 to phase III development

Omeros begins enrollment in second phase III OMS-302 trial

Preclinical studies demonstrate small molecule's efficacy to treat anterior uveitis

DARPin-based VEGF inhibitor completes phase IIa trial

Novartis seeks approval for Lucentis line extension

JDRF and iCo Therapeutics join to support iDEAL trial

Today's news in brief

Today's news in brief

Enhanced Cognition: Lewy body dementia phase II pumps stock

Second insulin receptor offers new therapeutic avenues

Experimental mRNA gene therapy suppresses preeclampsia in mice

Ocular RSS

Ocular
RSS